我国已建立每年一调的医保目录动态调整机制，聚焦5年内新上市药品。2025年新纳入的114种药品中，多个实现当年获批上市即进目录。2018年以来，我国1类创新药获批数量明显上升，2024年达48种，医保目录成其快速落地“加速器”，推动市场扩容。药企研发投入有稳定回报预期，将激励更多药企加大创新研发，尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右，约80%的...
Source Link我国已建立每年一调的医保目录动态调整机制，聚焦5年内新上市药品。2025年新纳入的114种药品中，多个实现当年获批上市即进目录。2018年以来，我国1类创新药获批数量明显上升，2024年达48种，医保目录成其快速落地“加速器”，推动市场扩容。药企研发投入有稳定回报预期，将激励更多药企加大创新研发，尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右，约80%的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.